SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on April 10, 2003; DOI 10.1182/blood-2003-02-0456. This Article Full Text (PDF) All Versions of this Article: 2003-02-0456v1 102/3/827    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Fukuda, T. Articles by Marr, K. A Search for Related Content PubMed PubMed Citation Articles by Fukuda, T. Articles by Marr, K. A Social Bookmarking                   What's this? Submitted February 11, 2003 Accepted March 29, 2003 Invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplantation after nonmyeloablative conditioning: risks and outcomes Takahiro Fukuda, Michael Boeckh, Rachel A Carter, Brenda M Sandmaier, Michael B Maris, David G Maloney, Paul J Martin, Rainer F Storb, and Kieren A Marr* Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA * Corresponding author; email: kmarr{at}fhcrc.org. The incidence of invasive mould infections has increased during the 1990s among allogeneic hematopoietic stem cell transplantation (HCT) recipients given myeloablative conditioning. In this study, we determined risk factors for invasive mould infection and mould infection-related death among 163 patients given allogeneic HCT with nonmyeloablative conditioning. The cumulative incidence rates of proven or probable invasive fungal infections, invasive mould infections, invasive aspergillosis, and invasive candidiasis during the first year after allogeneic HCT with nonmyeloablative conditioning were 19%, 15%, 14%, and 5%, respectively, which were similar to those after conventional myeloablative HCT. Invasive mould infections occurred late after nonmyeloablative conditioning (median, day 107), with primary risk factors including severe acute graft-versus-host disease (GVHD), chronic extensive GVHD, and cytomegalovirus (CMV) disease. The 1-year survival after diagnosis of mould infections was 32%. High-dose corticosteroid therapy at diagnosis of mould infection was associated with an increased risk for mould infection-related death. Overall, non-relapse mortality was estimated at 22% (36 patients) after nonmyeloablative conditioning, of which 39% (14 patients) were mould infection related (9% of the overall mortality). More effective strategies are needed to prevent invasive mould infections, which currently account for a notable proportion of non-relapse mortality after nonmyeloablative allogeneic HCT. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. T. Schiffer, K. Kirby, B. Sandmaier, R. Storb, L. Corey, and M. Boeckh Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation Haematologica, August 1, 2009; 94(8): 1101 - 1108. [Abstract] [Full Text] [PDF] J. L. Werner, A. E. Metz, D. Horn, T. R. Schoeb, M. M. Hewitt, L. M. Schwiebert, I. Faro-Trindade, G. D. Brown, and C. Steele Requisite Role for the Dectin-1 {beta}-Glucan Receptor in Pulmonary Defense against Aspergillus fumigatus J. Immunol., April 15, 2009; 182(8): 4938 - 4946. [Abstract] [Full Text] [PDF] R. Y. Hachem, D. P. Kontoyiannis, R. F. Chemaly, Y. Jiang, R. Reitzel, and I. Raad Utility of Galactomannan Enzyme Immunoassay and (1,3) {beta}-D-Glucan in Diagnosis of Invasive Fungal Infections: Low Sensitivity for Aspergillus fumigatus Infection in Hematologic Malignancy Patients J. Clin. Microbiol., January 1, 2009; 47(1): 129 - 133. [Abstract] [Full Text] [PDF] A. Burgos, T. E. Zaoutis, C. C. Dvorak, J. A. Hoffman, K. M. Knapp, J. J. Nania, P. Prasad, and W. J. Steinbach Pediatric Invasive Aspergillosis: A Multicenter Retrospective Analysis of 139 Contemporary Cases Pediatrics, May 1, 2008; 121(5): e1286 - e1294. [Abstract] [Full Text] [PDF] R. Bhabhra, D. L. Richie, H. S. Kim, W. C. Nierman, J. Fortwendel, J. P. Aris, J. C. Rhodes, and D. S. Askew Impaired Ribosome Biogenesis Disrupts the Integration between Morphogenesis and Nuclear Duplication during the Germination of Aspergillus fumigatus Eukaryot. Cell, April 1, 2008; 7(4): 575 - 583. [Abstract] [Full Text] [PDF] D. H. Dockrell Salvage therapy for invasive aspergillosis J. Antimicrob. Chemother., January 1, 2008; 61(suppl_1): i41 - i44. [Abstract] [Full Text] [PDF] O.S. Zmeili and A.O. Soubani Pulmonary aspergillosis: a clinical update QJM, June 1, 2007; 100(6): 317 - 334. [Abstract] [Full Text] [PDF] C. J. Clancy, R. A. Jaber, H. L. Leather, J. R. Wingard, B. Staley, L. J. Wheat, C. L. Cline, K. H. Rand, D. Schain, M. Baz, et al. Bronchoalveolar Lavage Galactomannan in Diagnosis of Invasive Pulmonary Aspergillosis among Solid-Organ Transplant Recipients J. Clin. Microbiol., June 1, 2007; 45(6): 1759 - 1765. [Abstract] [Full Text] [PDF] D. M. Hockenbery, S. Cruickshank, T. C. Rodell, T. Gooley, F. Schuening, S. Rowley, D. David, M. Brunvand, B. Berryman, S. Abhyankar, et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease Blood, May 15, 2007; 109(10): 4557 - 4563. [Abstract] [Full Text] [PDF] A. J. Ullmann, J. H. Lipton, D. H. Vesole, P. Chandrasekar, A. Langston, S. R. Tarantolo, H. Greinix, W. Morais de Azevedo, V. Reddy, N. Boparai, et al. Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease N. Engl. J. Med., January 25, 2007; 356(4): 335 - 347. [Abstract] [Full Text] [PDF] R. Martino, R. Parody, T. Fukuda, J. Maertens, K. Theunissen, A. Ho, G. J. Mufti, N. Kroger, A. R. Zander, D. Heim, et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation Blood, November 1, 2006; 108(9): 2928 - 2936. [Abstract] [Full Text] [PDF] O. Beck, M. S. Topp, U. Koehl, E. Roilides, M. Simitsopoulou, M. Hanisch, J. Sarfati, J. P. Latge, T. Klingebiel, H. Einsele, et al. Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus Blood, March 15, 2006; 107(6): 2562 - 2569. [Abstract] [Full Text] [PDF] F. Pene, C. Aubron, E. Azoulay, F. Blot, G. Thiery, B. Raynard, B. Schlemmer, G. Nitenberg, A. Buzyn, P. Arnaud, et al. Outcome of Critically Ill Allogeneic Hematopoietic Stem-Cell Transplantation Recipients: A Reappraisal of Indications for Organ Failure Supports J. Clin. Oncol., February 1, 2006; 24(4): 643 - 649. [Abstract] [Full Text] [PDF] J. M. Scotter and S. T. Chambers Comparison of Galactomannan Detection, PCR-Enzyme-Linked Immunosorbent Assay, and Real-Time PCR for Diagnosis of Invasive Aspergillosis in a Neutropenic Rat Model and Effect of Caspofungin Acetate Clin. Vaccine Immunol., November 1, 2005; 12(11): 1322 - 1327. [Abstract] [Full Text] [PDF] C. M. El Saleeby, K. J. Allison, K. M. Knapp, T. J. Walsh, and R. T. Hayden Discordant Rise in Galactomannan Antigenemia in a Patient with Resolving Aspergillosis, Renal Failure, and Ongoing Hemodialysis J. Clin. Microbiol., July 1, 2005; 43(7): 3560 - 3563. [Abstract] [Full Text] [PDF] M. L. Sorror, M. B. Maris, B. M. Sandmaier, B. E. Storer, M. J. Stuart, U. Hegenbart, E. Agura, T. R. Chauncey, J. Leis, M. Pulsipher, et al. Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia J. Clin. Oncol., June 1, 2005; 23(16): 3819 - 3829. [Abstract] [Full Text] [PDF] F. Baron, M. B. Maris, B. M. Sandmaier, B. E. Storer, M. Sorror, R. Diaconescu, A. E. Woolfrey, T. R. Chauncey, M. E.D. Flowers, M. Mielcarek, et al. Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning J. Clin. Oncol., March 20, 2005; 23(9): 1993 - 2003. [Abstract] [Full Text] [PDF] E. P. Alyea, H. T. Kim, V. Ho, C. Cutler, J. Gribben, D. J. DeAngelo, S. J. Lee, S. Windawi, J. Ritz, R. M. Stone, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age Blood, February 15, 2005; 105(4): 1810 - 1814. [Abstract] [Full Text] [PDF] N. Singh and D. L. Paterson Aspergillus Infections in Transplant Recipients Clin. Microbiol. Rev., January 1, 2005; 18(1): 44 - 69. [Abstract] [Full Text] [PDF] F. Baron, J. E. Baker, R. Storb, T. A. Gooley, B. M. Sandmaier, M. B. Maris, D. G. Maloney, S. Heimfeld, D. Oparin, E. Zellmer, et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning Blood, October 15, 2004; 104(8): 2254 - 2262. [Abstract] [Full Text] [PDF] D. Couriel, R. Saliba, K. Hicks, C. Ippoliti, M. de Lima, C. Hosing, I. Khouri, B. Andersson, J. Gajewski, M. Donato, et al. Tumor necrosis factor-{alpha} blockade for the treatment of acute GVHD Blood, August 1, 2004; 104(3): 649 - 654. [Abstract] [Full Text] [PDF] U. Schuler Reduced intensity conditioning before allografting: moderate enthusiasm may be more appropriate Eur. Respir. J., March 1, 2004; 23(3): 357 - 358. [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020